Full-Time

Senior Director

Clinical Sciences

Posted on 9/18/2024

Kymera Therapeutics

Kymera Therapeutics

201-500 employees

Develops targeted protein degradation therapies

Biotechnology
Healthcare

Senior, Expert

Belmont, MA, USA

Hybrid work model with a minimum of 3 days/week in the office.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Data Analysis
Google Cloud Platform
Requirements
  • A Bachelor’s Degree is required, with an advanced degree in life sciences or healthcare (PhD, MD, PharmD, MSc) preferred.
  • 10+ years of experience in clinical trial planning, startup, execution, reporting, and publishing within the biotech/pharma industry.
  • Demonstrated expertise in protocol development, study report and investigator brochure (IB) authoring, and preparing regulatory submissions.
  • Thorough knowledge of relevant regulatory guidelines, including GCP, ICH, and FDA standards, as well as a strong understanding of Quality practices within GCP.
  • Proven track record of successfully collaborating with medical monitors, development operations, and clinical investigators.
  • Proficiency in clinical trial management systems (CTMS) and databases.
  • Highly analytical and organized, with strong critical thinking skills and a history of innovative problem-solving.
  • Experience managing multiple tasks and priorities, especially under tight deadlines, with a keen attention to detail.
  • Ability to work independently, in multi-disciplinary teams, and with external partners, demonstrating strong interpersonal skills.
  • Exceptional communication skills, both written and verbal, with the ability to convey complex information clearly to diverse audiences.
  • Strong influencing abilities, with a history of resolving complex issues in creative and effective ways, and the capability to lead cross-functional teams.
Responsibilities
  • Contribute to the creation, design, and execution of Kymera’s clinical development strategy, collaborating with cross-functional teams (Biometrics, Regulatory, Clinical Operations) and external advisors.
  • Provide scientific leadership in clinical trial design, protocol development, and data analysis for early- and late-stage assets, ensuring adherence to FDA, EMEA, ICH, and GCP guidelines.
  • Serve as a member of the Clinical Study Team and Global Clinical Development SubTeam, participating in program meetings and safety monitoring reviews.
  • Manage internal and external communication of project updates, regulatory submissions, publications, and presentations.
  • Ensure patient safety by conducting clinical and medical data reviews, monitoring protocol adherence, and managing protocol deviations.
  • Collaborate with Clinical Operations and Data Management to ensure data accuracy and integrity, identify risks, and propose mitigation strategies, while maintaining consistent clinical data review practices across studies.
  • Stay current on disease biology, therapeutic practices, and drug mechanisms of action, providing insights into the competitive landscape and strategic development pathways.
  • Contribute to the preparation of scientific materials for conferences, publications, and presentations.

Kymera Therapeutics develops treatments by targeting and breaking down specific proteins that contribute to diseases, particularly cancer and immune disorders. Their main technology, the Pegasus Platform, enables them to identify these harmful proteins and create drug candidates aimed at effectively treating various conditions. Unlike many competitors, Kymera focuses on targeted protein degradation, which can lead to more precise therapies. The company's goal is to create next-generation medicines that address unmet medical needs, supported by partnerships with organizations like Sanofi to advance their research and development efforts.

Company Stage

IPO

Total Funding

$191.6M

Headquarters

Cambridge, Massachusetts

Founded

2016

Growth & Insights
Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

15%
Simplify Jobs

Simplify's Take

What believers are saying

  • Kymera raised $225 million to fund its pipeline and potential acquisitions.
  • The partnership with Neosphere Biotechnologies enhances molecular glue target discovery.
  • HSBC Holdings' investment indicates strong financial backing and confidence.

What critics are saying

  • Increased competition from companies like Arvinas and Nurix Therapeutics.
  • Potential regulatory delays could impact therapy market timelines.
  • Reliance on public offerings for funding poses financial instability risks.

What makes Kymera Therapeutics unique

  • Kymera's Pegasus Platform enables targeted protein degradation for disease-causing proteins.
  • The company focuses on developing therapies for cancer and immune disorders.
  • Kymera's collaboration with Sanofi advances novel protein degrader therapies.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE